|
1
|
Stewart BW and Wild CP: World Cancer
Report 2014International Agency for Research on Cancer. Lyon: World
Health Organization; 2014, View Article : Google Scholar
|
|
2
|
Abrams J, Conley B, Mooney M, Zwiebel J,
Chen A, Welch JJ, Takebe N, Malik S, McShane L, Korn E, et al:
National cancer institute's precision medicine initiatives for the
new national clinical trials network. Am Soc Clin Oncol Educ Book.
2014:71–76. 2014. View Article : Google Scholar
|
|
3
|
Couzin-Frankel J: Breakthrough of the year
2013. Cancer immunotherapy. Science. 342:1432–1433. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bernstein R: Translational research:
Cancer killers. Nature. 508:139–140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hontscha C, Borck Y, Zhou H, Messmer D and
Schmidt-Wolf IG: Clinical trials on CIK cells: First report of the
international registry on CIK cells (IRCC). J Cancer Res Clin
Oncol. 137:305–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stroncek D, Berlyne D, Fox B, Gee A,
Heimfeld S, Lindblad R, Loper K, McKenna D Jr, Rooney C, Sabatino
M, et al: Developments in clinical cell therapy. Cytotherapy.
12:425–428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang L, Wang J, Wei F, Wang K, Sun Q,
Yang F, Jin H, Zheng Y, Zhao H, Wang L, et al: Profiling the
dynamic expression of checkpoint molecules on cytokine-induced
killer cells from non-small-cell lung cancer patients. Oncotarget.
7:43604–43615. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosenberg S: Lymphokine-activated killer
cells: A new approach to immunotherapy of cancer. J Natl Cancer
Inst. 75:595–603. 1985.PubMed/NCBI
|
|
10
|
Rosenberg SA, Spiess P and Lafreniere R: A
new approach to the adoptive immunotherapy of cancer with
tumor-infiltrating lymphocytes. Science. 233:1318–1321. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yun YS, Hargrove ME and Ting CC: In vivo
antitumor activity of anti-CD3-induced activated killer cells.
Cancer Res. 49:4770–4774. 1989.PubMed/NCBI
|
|
12
|
Yang L, Ren B, Li H, Yu J, Cao S, Hao X
and Ren X: Enhanced antitumor effects of DC-activated CIKs to
chemotherapy treatment in a single cohort of advanced
non-small-cell lung cancer patients. Cancer Immunol Immunother.
62:65–73. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu J, Li H, Cao S, Zhang X, Yu J, Qi J,
An X, Yu W and Ren X: Maintenance therapy with autologous
cytokine-induced killer cells in patients with advanced epithelial
ovarian cancer after first-line treatment. J Immunother.
37:115–122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang X, Liu T, Zang X, Liu H, Wang D, Chen
H and Zhang B: Adoptive cellular immunotherapy in metastatic renal
cell carcinoma: A systematic review and meta-analysis. PLoS One.
8:e628472013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Luo H, Gong L, Zhu B, Huang Y, Tang C, Yu
S, Yang Z and Zhou X: Therapeutic outcomes of autologous CIK cells
as a maintenance therapy in the treatment of lung cancer patients:
A retrospective study. Biomed Pharmacother. 84:987–993. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kong DS, Nam DH, Kang SH, Lee JW, Chang
JH, Kim JH, Lim YJ, Koh YC, Chung YG, Kim JM and Kim CH: Phase III
randomized trial of autologous cytokine-induced killer cell
immunotherapy for newly diagnosed glioblastoma in korea.
Oncotarget. 8:7003–7013. 2017.PubMed/NCBI
|
|
17
|
Li X, Dai X, Shi L, Jiang Y, Chen X, Chen
L, Zhao J, Qiang W, Wu J, Ji M, et al: Phase II/III study of
radiofrequency ablation combined with cytokine-induced killer cells
treating colorectal liver metastases. Cell Physiol Biochem.
40:137–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leemhuis T, Wells S, Scheffold C, Edinger
M and Negrin RS: A phase I trial of autologous cytokine-induced
killer cells for the treatment of relapsed Hodgkin disease and
non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 11:181–187.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou C, Liu D, Li J, Sun H, Zheng X, Wang
S, Hong G, Mallampati S, Sun H, Zhou X, et al: Chemotherapy plus
dendritic cells co-cultured with cytokine-induced killer cells
versus chemotherapy alone to treat advanced non-small-cell lung
cancer: A meta-analysis. Oncotarget. 7:86500–86510. 2016.PubMed/NCBI
|
|
20
|
Banchereau J and Steinman RM: Dendritic
cells and the control of immunity. Nature. 392:245–252. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gallimore A and Godkin A: Regulatory T
cells and tumour immunity-observations in mice and men. Immunology.
123:157–163. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ,
Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW and Yoon JH: Adjuvant
immunotherapy with autologous cytokine-induced killer cells for
hepatocellular carcinoma. Gastroenterology. 148:1383–1391.e6. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao YJ, Jiang N, Song QK, Wu JP, Song YG,
Zhang HM, Chen F, Zhou L, Wang XL, Zhou XN, et al: Continuous
DC-CIK infusions restore CD8+ cellular immunity, physical activity
and improve clinical efficacy in advanced cancer patients
unresponsive to conventional treatments. Asian Pac J Cancer Prev.
16:2419–2423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li YC, Zhao L, Wu JP, Qu CX, Song QK and
Wang RB: Cytokine-induced killer cell infusion combined with
conventional treatments produced better prognosis for
hepatocellular carcinoma patients with barcelona clinic liver
cancer B or earlier stage: A systematic review and meta-analysis.
Cytotherapy. 18:1525–1531. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
World Health Organization, . WHO Handbook
for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO
Offset publication No. 48; 1979
|
|
26
|
Wu C, Jiang J, Shi L and Xu N: Prospective
study of chemotherapy in combination with cytokine-induced killer
cells in patients suffering from advanced non-small cell lung
cancer. Anticancer Res. 28:3997–4002. 2008.PubMed/NCBI
|
|
27
|
Sun S, Li XM, Li XD and Yang WS: Studies
on inducing apoptosis effects and mechanism of CIK cells for
MGC-803 gastric cancer cell lines. Cancer Biother Radiopharm.
20:173–180. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zou W: Regulatory T cells, tumor immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen B, Liu L, Xu H, Yang Y, Zhang L and
Zhang F: Effectiveness of immune therapy combined with chemotherapy
on the immune function and recurrence rate of cervical cancer. Exp
Ther Med. 9:1063–1067. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang ZX, Cao JX, Wang M, Li D, Cui YX,
Zhang XY, Liu JL and Li JL: Adoptive cellular immunotherapy for the
treatment of patients with breast cancer: A meta-analysis.
Cytotherapy. 16:934–945. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song G, Wang X, Jia J, Yuan Y, Wan F, Zhou
X, Yang H, Ren J, Gu J and Lyerly HK: Elevated level of peripheral
CD8(+)CD28(−) T lymphocytes are an independent predictor of
progression-free survival in patients with metastatic breast cancer
during the course of chemotherapy. Cancer Immunol Immunother.
62:1123–1130. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhong R, Han B and Zhong H: A prospective
study of the efficacy of a combination of autologous dendritic
cells, cytokine-induced killer cells, and chemotherapy in advanced
non-small cell lung cancer patients. Tumour Biol. 35:987–994. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
